Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis

[1]  M. T. Castells,et al.  Effect of atorvastatin and diet on non-alcoholic fatty liver disease activity score in hyperlipidemic chickens. , 2010, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[2]  L. Cubeddu,et al.  Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma. , 2010, Mayo Clinic proceedings.

[3]  Greger Lindberg,et al.  Decreased survival of subjects with elevated liver function tests during a 28‐year follow‐up , 2010, Hepatology.

[4]  K. Chayama,et al.  Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH , 2010, Journal of Gastroenterology.

[5]  M. Al Bakir,et al.  Prescribing statins to patients with nonalcoholic fatty liver disease: real cardiovascular benefits outweigh theoretical hepatotoxic risk. , 2009, Cardiovascular therapeutics.

[6]  M. Emdin,et al.  Additive prognostic value of gamma-glutamyltransferase in coronary artery disease. , 2009, International journal of cardiology.

[7]  Chunhong Bai,et al.  Long-term follow-up of patients with nonalcoholic fatty liver. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[8]  D. Mikhailidis,et al.  Pleiotropic effects of statins--clinical evidence. , 2009, Current pharmaceutical design.

[9]  N. Unwin,et al.  Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National , 2009 .

[10]  M. Rodríguez-Moran,et al.  Risk factors associated with nonalcoholic fatty liver disease and its relationship with the hepatic histological changes , 2008, European journal of gastroenterology & hepatology.

[11]  M. Monami,et al.  How many components for the metabolic syndrome? Results of exploratory factor analysis in the FIBAR study. , 2007, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[12]  James H. Lewis,et al.  Efficacy and safety of high‐dose pravastatin in hypercholesterolemic patients with well‐compensated chronic liver disease: Results of a prospective, randomized, double‐blind, placebo‐controlled, multicenter trial , 2007, Hepatology.

[13]  M. Mohseni,et al.  Prediction of coronary atherosclerotic disease with liver transaminase level , 2007, Liver international : official journal of the International Association for the Study of the Liver.

[14]  C. White,et al.  Impact of statin dosing intensity on transaminase and creatine kinase. , 2007, The American journal of medicine.

[15]  M. Holmqvist,et al.  Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. , 2007, Journal of hepatology.

[16]  A. Wierzbicki,et al.  The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[17]  M. Emdin,et al.  β-Lipoprotein- and LDL-associated serum γ-glutamyltransferase in patients with coronary atherosclerosis , 2006 .

[18]  A. Burroughs,et al.  Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study , 2006, Current medical research and opinion.

[19]  Jeanne M Clark,et al.  The Epidemiology of Nonalcoholic Fatty Liver Disease in Adults , 2006, Journal of clinical gastroenterology.

[20]  M. Emdin,et al.  Beta-lipoprotein- and LDL-associated serum gamma-glutamyltransferase in patients with coronary atherosclerosis. , 2006, Atherosclerosis.

[21]  J. Tsai,et al.  Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. , 2006, The American journal of cardiology.

[22]  F. Mach,et al.  Statins Reduce Interleukin-6–Induced C-Reactive Protein in Human Hepatocytes: New Evidence for Direct Antiinflammatory Effects of Statins , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[23]  A. Sanyal,et al.  Evaluation and management of non-alcoholic steatohepatitis. , 2005, Journal of hepatology.

[24]  M. Trovati,et al.  Prescription of statins to dyslipidemic patients affected by liver diseases: a subtle balance between risks and benefits. , 2004, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[25]  G. Lazaraki,et al.  Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia. , 2004, Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology.

[26]  M. Elisaf,et al.  The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study , 2004, Journal of Clinical Pathology.

[27]  M. Elisaf,et al.  Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[28]  D. Mikhailidis,et al.  Early Benefit from Structured Care with Atorvastatin in Patients with Coronary Heart Disease and Diabetes Mellitus , 2003, Angiology.

[29]  A. Wierzbicki,et al.  The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. , 2004, Current medical research and opinion.

[30]  K. Adeli,et al.  Treatment with atorvastatin ameliorates hepatic very-low-density lipoprotein overproduction in an animal model of insulin resistance, the fructose-fed Syrian golden hamster: evidence that reduced hypertriglyceridemia is accompanied by improved hepatic insulin sensitivity. , 2002, Metabolism: clinical and experimental.

[31]  V. Athyros,et al.  Treatment with Atorvastatin to the National Cholesterol Educational Program Goal Versus 'Usual' Care in Secondary Coronary Heart Disease Prevention , 2002, Current medical research and opinion.

[32]  American Gastroenterological Association medical position statement: nonalcoholic fatty liver disease. , 2002, Gastroenterology.

[33]  J. Mckenney,et al.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.